Our mission
Establishing a new R&D paradigm for innovative therapeutics
Symray is a biotech company focusing on research and development (R&D) of innovative antibody-based therapeutics. By using our well-established platforms including the all-species, all-epitope, and full-function antibody discovery platform, the high-throughput, automated antibody identification platform and the systematic, personalized drug verification platform, Symray constantly develop various mAbs, bi-specific Abs, antibody–drug conjugates and antibody fusion proteins, etc for unmet clinical needs. Our talented R&D team, state of art technology platforms, and sufficient readily available products enable us to thrive in the highly competitive early drug discovery market.
Learn more
By using our well-established antibody discovery, identification and verification platform, Symray is committed to linking innovation entities in the drug discovery community, by providing a platform of technology transfer for creative scientists, and high-quality drug pipelines for pharmaceutical companies. We have established a system for antibody drug development, that includes mAbs, bi-specific Abs, antibody–drug conjugates, antibody fusion proteins and CAR-T therapies. Our product pipeline covers multiple therapeutic areas including inflammation, autoimmune diseases, cardiovascular and metabolic disorders, ophthalmic diseases, and rare diseases.
Lead/PCC
Hits